within Pharmacolibrary.Drugs.ATC.L;

model L04AA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.12 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 15000 / 1000000,
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Antilymphocyte immunoglobulin (horse) is a polyclonal antibody preparation derived from the serum of horses immunized with human lymphocytes. It is primarily used as an immunosuppressive agent in the treatment and prevention of acute rejection in organ transplantation and in the management of aplastic anemia, particularly in patients unsuitable for stem cell transplantation. Its use has declined due to the availability of rabbit-derived preparations with a better safety profile, but it is still used in some regions.</p><h4>Pharmacokinetics</h4><p>No population pharmacokinetic studies or human pharmacokinetic parameter publications were identified for antithymocyte/antilymphocyte globulin (horse) in the scientific literature as of 2024. PK characteristics such as clearance or volume of distribution are largely unknown; estimates here are based on general immunoglobulin G pharmacokinetics and available dosing information.</p><h4>References</h4><ol><li><p>McGavin, JK, &amp; Goa, KL (2001). Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. <i>Drugs</i> 61(8) 1153–1183. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200161080-00016&quot;>10.2165/00003495-200161080-00016</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11465876/&quot;>https://pubmed.ncbi.nlm.nih.gov/11465876</a></p></li><li><p>Bunn, D, et al., &amp; Hendry, BM (1996). The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. <i>Clinical nephrology</i> 45(1) 29–32. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8616954/&quot;>https://pubmed.ncbi.nlm.nih.gov/8616954</a></p></li><li><p>Jing, LP, et al., &amp; Zhang, FK (2022). [Pharmacokinetic study of anti-human T-cell porcine immunoglobulin combined with cyclosporine A immunosuppressive therapy in patients with severe aplastic anemia]. <i>Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi</i> 43(4) 300–304. DOI:<a href=&quot;https://doi.org/10.3760/cma.j.issn.0253-2727.2022.04.006&quot;>10.3760/cma.j.issn.0253-2727.2022.04.006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35680628/&quot;>https://pubmed.ncbi.nlm.nih.gov/35680628</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AA03;
